Tags Posts tagged with "marijuana investing"

marijuana investing

2 1397
Marijuana Stocks Cannabis Stocks
 

mCig Inc. (MCIG) Broadens Construction Project Portfolio and Expands Cannabis Supply Division

 

mCig Inc. ( OTCQB : MCIG ), a diversified company servicing the legal cannabis, hemp and CBD markets, is pleased to announce the latest project updates for Grow Contractors (its construction and consulting division), in addition to the latest expansion of its cannabis supply division into the California cannabis market with record sales driven by recent recreational legalization in Nevada.

 

 


Click Here Now To Read (MCIG) Release


Marijuana Stocks on the Rise; What About Consumer Happiness?

 

Stocks in the medical marijuana industry have been hitting new highs for almost a year at this point, and the reasons behind it are quite obvious.

 



Click Here Now To Read Full Article


 

 

Nevada Marijuana Industry Spurs Growth For mCig (MCIG)

The opening of Nevada’s recreational marijuana market has been a catalyst to many companies, however, some have benefited more than others.

Some of the biggest beneficiaries have been the vertically integrated companies as well as the holding companies.

One company that has benefited the most is mCig Inc. (MCIG). The company is levered to several legal cannabis markets and it has benefited from its unique and significant exposure to the Nevada market.

 


Click Here Now To Read Full Article


0 1125
medical-marijuana-cancer-treatment

Well, he did it again. Acting DEA chief Chuck Rosenberg restated his oft-voiced opinion recently that “marijuana is not medicine.”

The Washington Examiner stated that he told an audience at a clinic in Cleveland: “If it turns out that there is something in smoked marijuana that helps people, that’s awesome. I will be the last person to stand in the way of that… But let’s run it through the Food and Drug Administration process, and let’s stick to the science on it.”

Former Surgeon General Vivek Murthy, appearing along with Rosenberg, added: “Should we be reducing the administrative and other barriers to researching that in the government? 100 percent. But what we should not do is make policies based on guesswork. When we do that, what we do is put people at risk.”

This is all outrageous hypocrisy.

Surely Murthy is aware of the Catch-22: Government bodies like the National Institutes of Health won’t fund the very studies he is calling for due to the cannabis’ illegality. Nonetheless, there have certainly been studies—no “guesswork” is needed.

The Hill pointed out that results of a placebo-controlled, randomized clinical trial were just recently published in the New England Journal of Medicine, finding that administration of the cannabinoid CBD significantly reduces seizure frequency in children with an otherwise drug-resistant form of epilepsy.

The findings prompted the study’s lead author, Orrin Devinsky of New York University’s Langone Medical Center, to pronounce: “Cannabis is approved in 20 countries for spasms in multiple sclerosis, so to say there’s no evidence of efficacy is simply untrue… They have to de-schedule this drug. It’s just not fair to the research and clinical communities, or to the patients. It’s medieval.”

Ironically, the government has at times actually recognized such research on the medicinal value of cannabis and cannabinoids.

In 2003, the U.S. Department of Health and Human Services secured a patent—number 6630507—for the use of cannabinoids as antoxidants and neuroprotectants, with potential application in fighting cancer and degenerative diseases. Yet in 2006, a U.S. Food and Drug Administration memo reiterated the official dogma that cannabis has “no medical value.”

This is bureaucratic schizophrenia, which can only be overcome by freeing up the research and taking oversight out of the hands of the DEA, a law enforcement body.

The House bill to remove cannabis from the “schedule list” of controlled substances entirely could accomplish this. The good news is that it actually has a Republican sponsor, Rep. Tom Garrett of Virginia. But whether it can muster enough votes to survive a presidential veto seems dubious—and advocates are still waiting for a coherent Trump position on cannabis.

marijuana-stocks-cannabis-update

Medical Marijuana Shows Parkinson’s Patient Some Relief

Ian Frizell, age 55, was diagnosed with Parkinson’ disease in 2011. He has suffered from symptoms since 1995, which continually got worse over time. Ian has filmed a video to display what a significant difference a small amount of medical marijuana makes to his tremors. In the clip, he states that he recently underwent deep brain stimulation surgery, a medical implant that helps hide the effects of Parkinson’s. He switches the DBS device off to show the seriousness of his tremors.

 


Click Here To View Full Article


 

Research Reveals Some Of Marijuana’s Health Effects

 

It may essentially help some people sleep and ease chronic pain, but it is also possible to heighten the danger of triggering a heart attack or develop schizophrenia. A Federal advisory panel came to those those conclusions about cannabis in a recent report.

The analysts also called for a…


Click Here To View Full Article


 

Vitality Biopharma (VBIO)

 

Vitality Biopharma (VBIO) has been in our spotlight for the better part of the last few weeks and we’ve seen this cannabis biotech deliver real potential for gains. What started out as a $0.98 alert ended up turning into a $4.24 bull. Even after pulling into $1.93, VBIO managed several clear bounces. This will be something we’ll be continuing to monitor into the later half of the month as well. If you haven’t taken a look at this company yet, check out our full report via the link below.


Click Here To View Full VBIO Report


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 2635
marijuana

 

What To Watch With Vitality Biopharma ($VBIO)

 

Vitality Biopharma (VBIO) is staying at the top of our list this week. We’ve witnessed first-hand how strong of a run that this has had and continues to have. Over the last few days we’ve seen VBIO hold a tend above $2.50, where last week it saw a trend in the higher $1 range. In fact since last week, VBIO is trending more than 30% higher than those previous lows. Keep in mind that within the last few weeks VBIO has hit highs of $4.23 so as many of you have already witnessed, this has been capable of dynamic breakouts over shorter periods of time.

This is all happening as the company continues to make progress with their novel therapies. has been going by route of prodrugs. Their unique approach targets CB2 receptors and can be taken orally to directly target specific tissues or organs. Right now, the company is working to create therapies for Crohn’s disease patients and those who suffer from inflammatory bowel disease. VBIO has filed intellectual property applications and is seeking worldwide patent protection through 2035, with strong composition of matter claims for its prodrugs.

In fact, the company’s novel use of certain developmental therapies have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. And if you remember, they’ve also just received the Drug Enforcement Administration’s approval for its pharma development facility…something that not many of its competitors (if any) can say right now especially in the current climate. Looking for more on VBIO?

 


Click Here To View Full VBIO Report



Things To Expect After Medical Cannabis Is Legal In Florida

Dr. Joseph Dorn was the medical director of Surterra Therapeutics, which is one of six distributing locations that are licensed to dispense medical marijuana in the state of Florida. The constitutional amendment allows higher-strength cannabis to be used for a broader range of medical conditions. However, the true measure of what the amendment means won’t be seen immediately until a new set of rules are carried out by the State’s Legislature.


Click Here To View Full Article


 

#ICYMI: Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

 

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.

 


Click Here To View Full Article


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

3 25771

Today is the final trading day of the year will definitely be one that investors will always remember. The market remains in the positive as companies are better positioned for success. From the advance of the Canadian marijuana industry to election of Donald Trump, there will be a lot for investors to watch next year. We would like to highlight some themes anticipated to play out over 2017.

Consolidation

One of the brightest spots of the marijuana industry in 2016 was the Canadian licensed medical marijuana producer sub-sector. In early December, Mettrum Health (MT.V)(MQTRF) and Canopy Growth (CGC.TO)(TWMJF) announced an agreement where Canopy Growth will gain all of the outstanding shares of Mettrum.

Keep your eyes on the marijuana industry as it is expected to see more deals like this over the next year. The possibility for increase consolidation makes these companies attractive investment opportunities: Aphiria (APH.V)(APHQF), Supreme (SL.V)(SPRWF), OrganiGram (OGI.V)(ORGMF), Emblem Corporation (EMC.V), and Aurora Cannabis (ACB.V)(ACBFF).

Transformation

The biotech sector will be one of the greatest recipients of the legal marijuana movement and recent sector weakness has created opportunities for investors.
GW Pharmaceuticals (GWPH) reported its second Stage Three Clinical trial in September for its Epidiolex product for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). We continue to view GWPH as one of the top marijuana investments due to its capability to convert the cannabis industry through the development of treatments for sickness’ that don’t currently have an approved regimen.

Execution

From the financial structure, investors need to conduct with earnestness. We suggest incorporating some guidelines into your investment blueprint.

To end 2016, we want to highlight some of the stocks investors should watch during next year: Emblem Corporation (EMC.V)(EMMBF), Zoned Properties (ZDPY), Aphria (APHQF), Kush Bottles (KSHB), American Cannabis (AMMJ), Aurora (ACBFF), Reliq Healthcare (RQHTF), Zynerba Pharmaceuticals (ZYNE), OrganiGram (OG.V)(ORGMF), Arcturus Grothstar Tech (AGSTF), MassRoots (MSRT), VPR Brands (VPRB), CV Sciences (CVSI), mCig (MCIG), Canopy Growth (TWMJF)(CGC.TO), Medicine Man Tech (MDCL), GW Pharmaceuticals (GWPH), Lexaria (LXRP), Canabo Medical (CMM.V)(CAMDF), Mettrum Health (MT.V), and VinergyRes (VIN.CN).

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements